ClinicalTrials.gov
public full text
Public Domain
Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS)
The purpose of this research is to find out if mexiletine is safe and effective in people with Amyotrophic Lateral Sclerosis (ALS). In this trial, participants will be taking either 300 milligrams per day of mexiletine, 900 milligrams per day of mexiletine or placebo (non-active study drug). The safety and efficacy of these doses will be compared to see if one dose is better than the other.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis#911913
- AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis#878064
- Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)#1339439
- Modafinil for Treatment of Fatigue in ALS Patients#1008003
- Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)#850951
Record · ID 1377452
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive